Nectero Therapeutics Receives FDA Fast Track Designation for Nectero EAST® System

TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm. Nectero Therapeutics is initiating […]